The Global Tribune

Thyroid eye disease Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight

 Breaking News
  • No posts were found

Thyroid eye disease Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight

February 17
20:04 2021
Thyroid eye disease Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight

Thyroid eye disease Market


(Albany, US) DelveInsight has launched a new report on Thyroid eye disease Market Insights, Epidemiology, and Market Forecast-2030.

DelveInsight’s ” Thyroid eye disease Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Thyroid eye disease, historical and forecasted epidemiology as well as the Thyroid eye disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.


Some of Thyroid eye disease Facts:

  • In a study by Zagaria et al. [2011], it was observed that approximately 25‐30% of patients with Graves’ disease have clinical evidence of Graves’ ophthalmopathy.
  • As per the study by Liaboe et al., titled “An Introductory Tutorial and Overview of Disease”, TED has a higher prevalence in women than men (16 per 100,000 vs. 3 per 100,000, respectively). Both men and women demonstrate a bimodal pattern of age of diagnosis(40–44 and 60–64 yearsin women; 45–49 and 65–69 years in men).
  • The study by Lazarus et al. titled “Epidemiology of Graves’ orbitopathy (GO and relationship with thyroid disease” estimates that Graves’ ophthalmopathy (GO) occurs mainly, but not exclusively, in patients with Graves’ disease. However, only about <50% of Graves’ patients have clinically apparent ophthalmopathy, where the approximate prevalence is 0.25%.
  • According to a review article titled “Epidemiology and Prevention of Graves’ Ophthalmopathy” by Wilmar et al., Graves’ ophthalmopathy is clinically relevant in approximately 50% of patients with Graves’ disease, and severe forms affects less than 5% of patients.


Request for Free Sample Report:


Scope of Thyroid eye disease report:

  • The report covers the descriptive overview of Thyroid eye disease, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Thyroid eye disease epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Thyroid eye disease are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Thyroid eye disease market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Thyroid eye disease market


Request for Free Sample Report:


Thyroid eye disease (TED)—also known as Graves’ Orbitopathy or Ophthalmopathy—is an autoimmune condition. It occurs when the body’s immune system attacks the tissue surrounding the eye causing inflammation in the tissues around and behind the eye. It appears that the same antibody that can cause thyroid dysfunction may also have an “attraction”to tissuessurrounding the eyes causing the onset of Graves’ Ophthalmopathy. Moreover, the disease is categorized as mild, moderate, and severe.

Some common symptoms of Graves’ Ophthalmopathy include feeling of irritation or grittiness in the eyes, redness or inflammation of the conjunctiva (the white part of the eyeball), excessive tearing or dry eyes, swelling of the eyelids, sensitivity to light, forward displacement or bulging of the eyes (called proptosis), and double vision. In more advanced eye disease there may also be decreased eye movement and eyelids, incomplete closure of the eye with corneal ulceration, compression of the optic nerve and rarely, loss of vision.

According to review article entitled “Epidemiology and Prevention of Graves’ Ophthalmopathy” by Wiersinga WM et al., the disease is more common in women than in men, although the female‐to‐male ratio is only 1:4 in severe forms of eye disease.


Some of Thyroid eye disease Companies:

  • Immunovant Sciences
  • Horizon Therapeutics
  • And Many Others


Thyroid eye disease Drugs Covered:

  • IMVT‐1401
  • Teprotumumab
  • And Many Others


Request for Free Sample Report:


Table of Contents:

1. Key Insights

2. Executive Summary of Thyroid eye disease

3. Competitive Intelligence Analysis for Thyroid eye disease

4. Thyroid eye disease: Market Overview at a Glance

5. Thyroid eye disease: Disease Background and Overview

6. Patient Journey

7. Thyroid eye disease Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Thyroid eye disease Treatment

11. Marketed Products

12. Emerging Therapies

13. Thyroid eye disease: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Thyroid eye disease

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight


Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States